Key result
Adding NT-proBNP improves clinical model prediction of two-year mortality, transplant, or LVAD in chronic HF.
Why the study?
Guidelines recommend predicting chronic heart failure prognosis using natriuretic peptides, NYHA classification, and comorbidities, prompting the development of a prognostic score integrating these factors.
Does adding NT-proBNP to clinical parameters improve the prediction of two-year mortality, heart transplantation, or LVAD implantation in patients with HFrEF and HFmrEF?
Cohort (n=1,088)
Does adding NT-proBNP to clinical parameters improve the prediction of two-year mortality, heart transplantation, or LVAD implantation in patients with HFrEF and HFmrEF?
Answers are grounded in this paper and cite their sources.
Adding NT-proBNP to a clinical prediction model improves prognostic accuracy for 2-year adverse outcomes in patients with HFrEF and HFmrEF.
BACKGROUND: According to guidelines, the prognosis of patients with chronic heart failure can be predicted by determining the levels of natriuretic peptides, the NYHA classification and comorbidities. The aim our work was to develop a prognostic score in chronic heart failure patients that would take account of patients' comorbidities, NYHA and NT-proBNP levels. METHODS AND RESULTS: A total of 1,088 patients with chronic heart failure with reduced ejection fraction (HFrEF) (LVEF<40%) and mid-range EF (HFmrEF) (LVEF 40-49%) were enrolled consecutively. Two-year all-cause mortality, heart transplantation and/or LVAD implantation were defined as the primary endpoint (EP). The occurrence of EP was 14.9% and grew with higher NYHA, namely 4.9% (NYHA I), 11.4% (NYHA II) and 27.8% (NYHA III-IV) (p<0.001). The occurrence of EP was 3%, 10% and 15-37% in patients with NT-proBNP levels ≤125 ng/L, 126-1000 ng/L and >1000 ng/L respectively. Discrimination abilities of NYHA and NT-proBNP were AUC 0.670 (p<0.001) and AUC 0.722 (p<0.001) respectively. The predictive value of the developed clinical model, which took account of older age, advanced heart failure (NYHA III+IV), anaemia, hyponatraemia, hyperuricaemia and being on a higher dose of furosemide (>40 mg daily) (AUC 0.773; p<0.001) was increased by adding the NT-proBNP level (AUC 0.790). CONCLUSION: The use of prediction models in patients with chronic heart failure, namely those taking account of natriuretic peptides, should become a standard in routine clinical practice. It might contribute to a better identification of a high-risk group of patients in which more intense treatment needs to be considered, such as heart transplantation or LVAD implantation.
No takes yet. Share an insight, caveat, or question.
Špinar et al. (2019) conducted a cohort in Chronic heart failure with mid-range and reduced ejection fraction (n=1,088). NT-proBNP addition to clinical parameters vs. Clinical parameters alone was evaluated on Two-year all-cause mortality, heart transplantation and/or LVAD implantation (AUC 0.790, p=<0.001). Adding NT-proBNP to a clinical model improved the prediction of two-year all-cause mortality, heart transplantation, or LVAD implantation in chronic heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: